Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report
European Heart Journal - Case Reports · 01.02.2025 · 9 (2)
DOI: 10.1093/ehjcr/ytaf019 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Heart Journal - Case Reports, online erschienen am 17.02.2025. Verfasst von Elena Wadden und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Washington Medical Center, 1959 NE Pacific Street, Health Sciences Building, Seattle, WA 98195, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy with growing indications for treatment of various malignancies. Immune checkpoint inhibitors are monoclonal antibodies that block inhibitory pathways in immune cells, including cytotoxic T lymphocyte antigen-4 (CTLA4), programmed death 1 receptor (PD1), and programmed cell death ligand-1 (PDL1), to activate the immune system. However, these agents can disrupt self-tolerance and lead to immune-related adverse events. Fulminant myocarditis, a feared complication of ICIs, can be highly fatal, and there is a need for effective treatment options. Case summary A 70-year-old patient with recurrent metastatic disease of urothelial carcinoma subsequently developed fulminant myocarditis after receiving eight cycles of pembrolizumab. He developed cardiogenic shock and required inotropes and a percutaneous microaxial flow pump placement for temporary mechanical circulatory support. He received methylprednisolone initially and then was started on second-line immunosuppression agents, ruxolitinib and abatacept, for steroid-refractory myocarditis. Abatacept is thought to inhibit activation of T-cell CTLA4 and PD1/PDL1 pathways and reverse ICI-activated pathways. Ruxolitinib is a Janus kinase inhibitor that impairs immune activation through suppressing cytokine sensing and production and T-cell activation. After these treatments, the patient subsequently clinically improved and his myocarditis resolved.
Discussion
This case highlights ICI myocarditis refractory to corticosteroids leading to treatment with second-line immunosuppression. As immunotherapies are increasingly applied to a broader range of cancers, further research is needed to evaluate the optimal treatment strategy for ICI-related myocarditis and other immune-related adverse events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, University of Washington Medical Center, 1959 NE Pacific Street, Health Sciences Building, Seattle, WA 98195, USA.
- Department of Cardiology, Straub Medical Center, 888 S King St, Honolulu, HI 96813, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, P.O. Box 19024, Seattle, WA 98109, USA.
- Division of Hematology and Oncology, University of Washington School of Medicine, 825 Eastlake Ave. E, Seattle, WA 98109, USA.
- Department of Pharmacology, Sorbonne Université, INSERM, AP-HP, CIC-1901, Pitié-Salpêtrière Hospital, Paris, France.
- Section of Cardio-Oncology and Immunology, University of California San Francisco, Smith Cardiovascular Research Building, 535 Mission Bay Blvd. South, San Francisco, CA 94158, USA.
ORCID-Profile: Elena Wadden
Zitieren
APA
Wadden, E., Lai, C., Grivas, P., Bhatia, S., Portuguese, A. J., Salem, J. E., Moslehi, J. J., & Cheng, R. K. (2025). Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report. European Heart Journal - Case Reports, 9(2). https://doi.org/10.1093/ehjcr/ytaf019
Vancouver
Wadden E, Lai C, Grivas P, Bhatia S, Portuguese AJ, Salem JE, et al. Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report. European Heart Journal - Case Reports. 2025;9(2). doi:10.1093/ehjcr/ytaf019
BibTeX
@article{Wadden2025,
author = {Wadden, Elena and Lai, Carol and Grivas, Petros and Bhatia, Shailender and Portuguese, Andrew J and Salem, Joe-Elie and Moslehi, Javid J and Cheng, Richard K},
title = {Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report},
journal = {European Heart Journal - Case Reports},
year = {2025},
volume = {9},
number = {2},
doi = {10.1093/ehjcr/ytaf019}
}
EUVIMED